Ainos AIMD
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Ainos (AIMD)
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
Key Insights
Critical company metrics and information
Latest Closing Price
$0.489Market Cap
$6.89 MillionPrice-Earnings Ratio
-0.31Total Outstanding Shares
14.09 Million SharesTotal Employees
46Dividend
No dividendIPO Date
August 8, 1996SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
Ainos, inc., San diego, CA, 92108Homepage
https://www.ainos.com
Historical Stock Splits
If you bought 75 shares of AIMD before August 9, 2022, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| December 14, 2023 | 1-for-5 (Reverse Split) |
| August 9, 2022 | 1-for-15 (Reverse Split) |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $8.03 Million |
| Net Cash Flow From Investing Activities, Continuing | $-125,292 |
| Net Cash Flow, Continuing | $2.09 Million |
| Net Cash Flow From Operating Activities | $-5.81 Million |
| Net Cash Flow From Investing Activities | $-125,292 |
| Net Cash Flow From Operating Activities, Continuing | $-5.81 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $-1.56 |
| Operating Expenses | $13.81 Million |
| Income Tax Expense/Benefit | $800 |
| Income/Loss From Continuing Operations After Tax | $-14.86 Million |
| Nonoperating Income/Loss | $-1.02 Million |
| Costs And Expenses | $14.88 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-15.00 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-15.00 Million |
| Comprehensive Income/Loss Attributable To Parent | $-15.00 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $9.35 Million |
| Equity Attributable To Parent | $15.52 Million |
| Inventory | $143,756 |
| Current Assets | $4.34 Million |
| Current Liabilities | $3.95 Million |
| Liabilities And Equity | $28.82 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about AIMD from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.